Randomized Controlled Clinical Trial of Blood Glucose Awareness Training (BGAT III) in Switzerland and Germany by Schachinger, Hartmut et al.
Journal of Behavioral Medicine, Vol. 28, No. 6, December 2005 ( C© 2005)
DOI: 10.1007/s10865-005-9026-3
Randomized Controlled Clinical Trial of Blood Glucose
Awareness Training (BGAT III) in Switzerland
and Germany
Hartmut Schachinger,1,2,8 Karin Hegar,2,3 Norbert Hermanns,4 Madeleine Straumann,5
Ulrich Keller,3 Gabriele Fehm-Wolfsdorf,6 Willi Berger,3 and Daniel Cox7
Accepted for publication: March 30, 2005; Published online: October 13, 2005
Although both diabetes and the efficacy of medical management are international issues,
psycho-educational interventions might be culturally bound. Blood Glucose Awareness
Training (BGAT) is a psycho-educational program for patients with type 1 diabetes mellitus.
It is focused on improving recognition and management of extreme blood glucose levels, and
is the best documented American psycho-educational program for this purpose. A random-
ized controlled clinical trial of BGAT’s long-term benefits in a non-American setting has
been lacking. One hundred and eleven adults with type 1 diabetes mellitus from Switzerland
and Germany participated. After a 6 months baseline assessment, subjects were randomly
assigned to receive either 2 months of BGAT (n = 56) or a physician-guided self-help control
intervention (n = 55). BGAT improved recognition of low (p = 0.008), high (p = .03), and
overall blood glucose (p = 0.001), and reduced frequency of severe hypoglycemia (p = 0.04),
without compromising metabolic control. BGAT reduced both the external locus of control
(p < 0.02) and fear of hypoglycemia (p < 0.02). BGAT was efficacious in reducing adverse
clinical events and achieving clinically desirable goals in a European, as well as American
setting.
KEY WORDS: blood glucose awareness training; severe hypoglycemia; psycho-educational program;
clinical trial; hypoglycemia fear.
INTRODUCTION
The central goal of type 1 diabetes mellitus
management is to normalize blood glucose lev-
els while avoiding extreme blood glucose values
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(hypoglycemia and hyperglycemia). Although the
long-term risks associated with hyperglycemia are
generally well recognized by patients and health
care professionals, the potential hazards of hypo-
glycemia require more attention (Muhlhauser et al.,
2002). During hypoglycemia, significant negative
sequelae can occur, including emotional stress for
patients (Gonder-Frederick et al., 1997a) and their
significant others (Gonder-Frederick et al., 1997b;
Stahl et al., 1998), accidents (Cox et al., 2003), and
even death (Sovik and Thordarson, 1999). Symptom
recognition and accurate detection of extreme blood
glucose values are crucial for management of type 1
diabetes mellitus. Symptoms of hyperglycemia and
Abbreviations:, BGAT: Blood Glucose Awareness Training,
T0: baseline, T1: 1–6 months after intervention, T2: 7–12 months
after intervention
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hypoglycemia may be minimal, misinterpreted or
neglected.
Blood Glucose Awareness Training (BGAT) is
a psycho-educational self-management program de-
signed to assist adults with type 1 diabetes mellitus
to prevent extreme blood glucose values, and better
recognize and treat hyperglycemia and hypoglycemia
when they occur. BGAT is typically delivered to
outpatients in a group format, over an 8 weeks pe-
riod. The focus is on teaching patients to identify
their individual symptoms suggestive of the extreme
blood glucose fluctuations (internal cues) as well as
when and how to anticipate blood glucose extremes
based on food, exercise, and insulin regimens (exter-
nal cues).
Participants are instructed to read the appropri-
ate chapter immediately before the class, discuss the
personal relevance of the text during the class, and
between classes perform homework exercises evalu-
ating the personal relevance of the chapter’s content.
There have been three editions of BGAT, an ini-
tial six chapter version that emphasized internal cues,
an eight chapter version focusing on both internal
and external cues (BGAT II; Cox et al., 1991, 2001),
and an updated version incorporating newer insulins
and in which Chapter 8 addresses long-term main-
tenance (BGAT III; Kinsley et al., 1999). The effi-
cacy of BGAT has been well documented in the USA
(Cox et al., 1988, 1991, 2001; Kinsley et al., 1999), with
benefits including not only improved blood glucose
estimate accuracy, but a dramatic decrease in auto-
mobile accidents as well.
However, a European study evaluating BGAT I
(Broers et al., 2002) found it to significantly re-
duce fluctuations in blood glucose but only marginal
benefits in improving detection of hypoglycemia
and raising questions regarding treatment gen-
eralizability. In addition, cultural differences in
the applicability of psycho-educational approaches
might lead to varying efficacy in a European set-
ting. Therefore, a randomized controlled prospec-
tive study of BGAT in European settings was
undertaken.
The following hypotheses were tested: (1)
BGAT III would lead to improved blood glucose es-
timation, (2) a reduction in the frequency of extreme
blood glucose levels, (3) decrease in the frequency of
severe hypoglycemia; and (4) improved psychologi-
cal functioning in terms of greater internal locus of
control and less fear of hypoglycemia. In addition,
the effect of BGAT on relevant psychological vari-
ables was examined.
SUBJECTS, MATERIALS AND METHODS
Subjects and Research Centers
The research was approved by the Ethics Com-
mittee of the Basel University Hospital. Six sites
in Switzerland and Germany participated in this
prospective multi-center study (see appendix for de-
tails). Study information was made available to type
1 diabetes mellitus subjects by conventional mail,
oral communications, and posters located in the di-
abetes specialist’s office at each site, regardless of se-
vere hypoglycemia history. However, patients known
to the physicians as having recurrent severe hypo-
glycemia were (often successfully) encouraged to
participate. The estimated number of type 1 dia-
bets mellitus subjects being aware of this program
is about 400. However, it is impossible to determine
the exact number. Subjects who indicated interest
were invited to a group information session. Those
deciding to participate in the study were individu-
ally interviewed, as were their diabetes specialists
and/or family physicians (focusing on their diabetes
treatment, diabetes complications, and psychiatric
comorbidity).
Exclusion criteria were uncontrolled physical
(i.e., heart or vascular disease) and mental dis-
eases (i.e., depression, eating disorder, and substance
abuse) at the time of claimed interest in the program.
Somatic comorbidity was assessed by diabetes spe-
cialist or family physicians. Diabetes specialists or
family physicians transferred their patients to psy-
chiatrists or the psychosomatic medicine outpatient
clinic in case of suspected psychiatric or psychoso-
matic comorbidity. Comorbidity was considered un-
controlled when newly diagnosed or new treatment
had to be established within the last 3 months prior
to supposed study entry. Study entrance had to be
retarded in six patients because of these criteria.
Substance dependency and illicit drug use was as-
sessed by self-report data: any use of cannabis prod-
ucts, benzodiazepines, or barbiturates within the last
2 years, and more than 30 g ethyl alcohol per day.
Interestingly, in this sample of middle-aged type 1 di-
abetes mellitus subjects there was no case qualifying
for these criteria.
It was verified that the subjects were on a
‘state of the art’ intensified insulin regimen, per-
formed three to five injections and at least three
blood glucose measurements per day, had a recent
adjustment of insulin dose and dosing sched-
ule (if necessary), and routine determination of
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glycosylated hemoglobin (HbA1c) every 3 months.
All patients provided informed consent and were
made aware of their right to discontinue participa-
tion in the study at any time.
Study Design
A total of 138 subjects decided to participate
in the study. After a 6-month baseline assessment
period (T0), subjects were randomly assigned to
receive either BGAT or to participate in a physician-
guided self-help group (control). Because age and
diabetes mellitus duration (Gold et al., 1997) are
important confounders favoring the occurence of
severe hypoglycemia, subjects were matched to con-
trols within each research center for approximate age
and duration of diabetes. At each research center, at
least one BGAT group and one control group inter-
vention were offered. The randomization procedure
was as follows: within each research center, patients
were grouped as pairs of approximately the same
age and diabetes duration. Then, a random decision
was made as to who of the two patients received
BGAT. The other patient received the control group
intervention.
Fourteen subjects attended fewer than 50% of
the training sessions (eight in the control group and
six in the BGAT group) and were not included in the
statistical analyses. The two post-intervention mea-
surement periods were at 1–6 months (T1) and 7–12
months (T2) post-intervention. Data was collected at
the end of the 6 months period. Thirteen subjects (six
controls) who were noncompliant with these follow-
up examinations were also excluded from analyses.
Baseline characteristics of the drop-out patients and
the remaining 111 subjects (80% of all randomized
subjects) are reported in Table I, they did not differ
between participating subjects and drop-out patients.
However, glycosylated hemoglobin of drop-outs was
7.26% (0.99) indicating worse metabolic control in
these subjects (Savage non-parametric two-sample
test: p = 0.05).
Sixty-one percent of the patients had a cohabit-
ing partner. Patients with partners did not differ from
patients without partners in hypoglycemic event rate.
However, patients with partners had lower glycosy-
lated hemoglobin, especially those patients without
severe hypoglycemia in the previous 2 years. The in-
fluence of partnership on diabetes-related psychoso-
cial functions will be the focus of another manuscript
currently in preparation.
Interventions
The German version of BGAT III (Lu¨beck
Institute for Behavioral Medicine, Fleischhauerstr.
26, 23552 Lu¨beck, Germany) was delivered by
a physician–psychologist team to groups of 5–12
subjects in eight weekly sessions. To assure sufficient
quality across study sites, one of the two BGAT
group leaders was a trained psychologist from the
Basel core study team. Each BGAT session lasted
for about 2 h. The introductory session (Chapter 1) is
followed by three sessions focusing on the so-called
‘internal cues’ (physical symptoms; Chapter 2),
disruptions in cognitive and motor performance
(Chapter 3), and mood changes (Chapter 4). Patients
are taught to use these signals to more accurately
recognize when their blood glucose is too high
or low. The next three chapters focus on how to
use ‘exogenous cues’: previous insulin injections
(Chapter 5), food consumption (Chapter 6), and
physical exercise (Chapter 7) to better anticipate
when blood glucose is likely to rise or fall. Chapter
8 reviews the subject’s personal observations from
BGAT and discusses ways to maintain BGAT ben-
Table I. Baseline Characteristics
Variable BGAT (n = 56) Control (n = 55) Drop-outs (n = 27)
Sex (female/male) 25/31 21/34 12/15
Age (years) 45 (14.4) 47.9 (13.1) 48.1 (13.4)
Diabetes duration (years) 23.1 (12) 22.7 (12.2) 22.5 (13.9)
Body mass index (kg/m2) 24.5 (4.5) 23.4 (3.5) 24.2 (4.1)
During last 2 years before study
Patients with severe hypoglycemia (%) 64 47 50
Patients with hypoglycemic coma (%) 28 25 33
During last 6 months before study
Motor vehicle accidents (n) 2 2 0
Hospitalization (any cause) (n) 5 6 7
Diabetic ketoacidosis (n) 0 1 1
Note. Severe hypoglycemia (help of others required), Means and SD is reported.
590 Schachinger et al.
efits. Weekly homework and preparatory readings
were required.
The self-help control group was guided by one
physician. Five to twelve subjects participated in
three monthly sessions. Each control group session
lasted for about 2 h. The focus of the sessions was:
‘current problems related to diabetes,’ ‘stress and di-
abetes,’ ‘anatomy and physiology,’ ‘physical activity,’
‘diabetes in the workplace,’ ‘relationship conflicts,’
and ‘previous experiences’; however, participants de-
termined the specific issues and timing. There was no
homework assigned to the control group.
Dependent Variables
All the subjects were instructed to use 2 month
diaries developed for this study. Diaries were such
that patients could easily insert date and time of
measurement, blood glucose estimation, actual
blood glucose values, and remarks. Important tele-
phone numbers and mailing addresses (study center,
psychologists) were provided on the inside of the
cover pages. Patients tested blood glucose at least
three times daily. The testing schedule was subject
to individual patient—physician communications.
However, most of the patients tested blood glucose
four times: fasting blood glucose (after awakening),
pre-prandial blood glucose values (before supper and
lunch), and before bed-time. BGAT did not affect
the number of blood glucose measurements. Severe
hypoglycemia was defined as any hypoglycemic
episode for which the help of others was required
(Tattersall, 1999). Severe hypoglycemia was assessed
by means of these blood glucose diaries, as well
as questionnaires at 6 and 12 months assessments.
Diaries and questionnaires gave the same results,
with only some exceptions. If necessary, patients,
partners, and physicians were interviewed to clarify
discrepant reports. It was not possible to routinely
verify hypoglycemic events against glucometer re-
sults because of logistic difficulties. Sixty-one percent
of patients shared their household with a partner.
Cohabiting partners were always contacted when
severe hypoglycemia was reported as to verify the oc-
currence of this event. Hand-held computers (Clarke
et al., 1995) are known to increase the reliability of
blood glucose estimations, but do not guarantee cor-
rect report of actual blood glucose values. They were
not used in the current study. A period of at least 3
consecutive weeks with complete data pairs of blood
glucose estimations and measurements was neces-
sary for each individual patient and assessment point
for the subject to be included in analyses. Blood
glucose accuracy index (Clarke et al., 1987; Cox
et al., 1989), detection of low ( < 4 mmol/L) and high
( > 10 mmol/L) blood glucose levels, as well as low
and high blood glucose risk index (Cox et al., 1994b;
Kovatchev et al., 1998) were calculated according to
the published standards. Blood glucose thresholds
for hypoglycemia symptoms were reported by the
subjects based on regular self monitoring blood
glucose, they represent subjective estimates.
Standardized questionnaires were used to as-
sess diabetes specific locus of control (Kohlmann
et al., 1995), and both diabetes specific (Bradley,
1994; The DCCT Research Group, 1988) and general
(Dahlbert, 1992) quality of life measures.
The diabetes-specific locus of control ques-
tionnaire was used at T0 and T2, only. It measures
four distinct scales: internalization, externalization,
unpredictability, and chance control. Internal consis-
tencies range between (Cronbach’s alpha) 0.79 and
0.83. Test–retest reliability scores (6 months interval)
range between r = 0.72 and r = 0.78. This question-
naire is available in German, only (Kohlmann et al.,
1995).
The Well-Being Questionnaire from Bradley is a
validated 22-item instrument containing no somatic
items to minimize potential direct effects of poor
metabolic control. It was developed specifically for
use with diabetic individuals and has been shown to
have good reliability and validity (Bradley, 1994). It
produces four subscales that assess depression, anx-
iety, positive well-being, and perceived energy over
the previous 7 days. The Well-Being Questionnaire
has been applied successfully in the recent research
(Paschalides et al., 2004).
The specific Diabetes Quality-of-Life question-
naire was developed for insulin-treated diabetes pa-
tients. It measures the scales: satisfaction, impact and
diabetes-related worry. All scales were found to have
high internal consistencies between 0.66 and 0.92 and
excellent test–retest reliability between r = 0.78 and
r = 0.92 (The DCCT Research Group, 1988).
A 19-item mood questionnaire was also em-
ployed which is available in German, only. It mea-
sures 4 scales (fatigue, hopelessness, negative mood,
and positive mood), validation studies revealed in-
ternal consistencies ranging between 0.83 and 0.94
(Dahlbert, 1992).
The patients also completed the Hypoglycemia
Fear Survey (Irvine et al., 1994) ‘worry’ and ‘be-
havior’ subscales. The Hypoglycemia Fear Survey
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worry subscale is based on reactions to severe
hypoglycemia episodes (Gold et al., 1997). Thus,
the impact of BGAT on fear of hypoglycemia was
analyzed in the subsample of patients who had
experienced a severe hypoglycemic episode within
the 2 years, prior to participation in this study.
Glycosylated hemoglobin (HbA1c; upper limit
of normal range: 6.1–6.3%) was determined by an
immuno-enzymatic method (DCA, 2000); this data
was provided by diabetes specialists or family physi-
cians.
Statistical Analysis
A repeated measures Analysis of Variance
(ANOVA) was used to examine the impact of
treatment (between subjects factor: BGAT vs. Con-
trols) and time (within subjects factor: Baseline/T0
vs. 1–6 month/T1 vs. 7–12 month/T2 follow-up).
The primary statistic of concern was a significant
interaction term. Contrasts were constructed a priori
for comparison of T1 vs. T0 and T2 vs. T0. Including
‘severe hypoglycemia in the previous 2 years’ as a
covariate in the model did not have a significant
effect on the results, so to preserve statistical power,
the covariate was not included in the final model.
Mean and standard deviation (SD) are reported
in tables and text. All the testings were two-tailed.
Statistical calculations were performed using SAS
(Version 8, WinNT, SAS Institute, Cary, NC, USA).
RESULTS
There was a marginal tendency (chi square
statistic, p = 0.07) for a greater prevalence of severe
hypoglycemia during the 2 years before entry into
the study in the BGAT group. The incidence of mo-
tor vehicle accidents, hospitalization for any cause,
and diabetic ketoacidosis was low in both groups (see
Table I). Age, diabetes duration, and body mass in-
dex were comparable between groups (see Table I).
The blood glucose estimation and measurement
pairs per subject and assessment period (BGAT-
T0: 233 ± 195 [n = 54], T1: 221 ± 124 [n = 45], T2:
203 ± 129 [n = 46]; CNT-T0: 233 ± 90 [n = 50],
T1: 221 ± 127 [n = 46], and T2: 203 ± 123 [n = 47]
(mean ± SD)) were sufficiently numerous and
comparable in time and between groups.
BGAT led to a decrease in severe hypoglycemic
episodes and increased recognition of low and high
blood glucose levels, so as to improve accuracy in-
dex and subjective recognition threshold for hypo-
glycemia symptoms (see Table II). Extreme blood
glucose fluctuations and glycosylated hemoglobin
were not influenced by treatment (see Table II). Lo-
cus of control became less external, and treated sub-
jects also experienced less unpredictability related
to diabetes (see Table III). The behavior-subscale
scores of the Hypoglycemia Fear Survey decreased
in the BGAT group (indicating less endorsement of
behaviors related to hypoglycemia fear), but initial
values were higher in this group, so the results might
or might not be due to the intervention. There was no
impact of BGAT on the Hypoglycemia Fear Survey
worry subscale when the entire sample was analyzed
(see Table IV). However, when only patients with a
history of severe hypoglycemia were analyzed, scores
on the worry subscale indicated a reduction in fear
for the BGAT group (see Table IV). There was no
overall effect of BGAT on either diabetes specific or
general quality of life measures.
DISCUSSION
The present study demonstrates BGAT’s effi-
cacy in reducing adverse clinical events (severe hypo-
glycemia), without compromising metabolic control
and achieving clinically desirable goals (improved
recognition of low and high blood glucose, reduced
external locus of control and reduced fear of hypo-
glycemia) in European settings.
The results of this study are in accordance with
previous findings in USA type 1 diabetes melli-
tus samples. BGAT has been shown to improve
the accuracy of blood glucose estimation and detec-
tion of hypoglycemia (Cox et al., 1994a, 2001), im-
prove decisions to treat low blood glucose and not
to drive while experiencing low blood glucose lev-
els (Cox et al., 2001), reduce frequency of severe
hypoglycemia (Cox et al., 1995, 2001), reduce fre-
quency of ketoacidosis (Cox et al., 2001) and mo-
tor cycle accidents (Cox et al., 1994a, 2001), reduc-
tion in fear of hypoglycemia and increased quality
of life (Cox et al., 2001), and improve the counter-
regulatory response to hypoglycemia (Kinsley et al.,
1999). We now can add that BGAT reduced exter-
nal locus of control and increased predictability con-
cerning diabetes-specific issues, and that BGAT in-
creased hypoglycemia symptom thresholds.
Hypoglycemia unawareness is a major contrib-
utor to the problem of severe hypoglycemia. BGAT
has been demonstrated to increase the blood glucose
awareness effectively in the USA, but a Dutch report
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Table II. Effects of BGAT on Hypoglycemia Rate, Recognition of BG Levels, and Metabolic Control
Variable T0 T1 T2
Time × Group
interaction; F, p
Contrast T1 vs.
T0 group
effect; F, p
Contrast T2 vs.
T0 group
effect; F, p
Negative consequences
Severe hypoglycemia (episodes/6 months)
BGAT (n = 56) 1.61 (3.49) 0.13 (0.33) 0.13 (0.33) F(2,218) = 3.14 F(1,109) = 1.73 F(1,109) = 4.04
Control (n = 55) 1.76 (3.71) 1.07 (2.85) 1.78 (4.56) p = 0.04 p = 0.19 p = 0.04
Recognition of BG levels
Percent detection of low blood glucose levels
BGAT (n = 33) 52.7 (21.8) 58.2 (24.8) 65.2 (25.2) F(2,132) = 4.92 F(1,66) = 3.79 F(1.66) = 8.39
Control (n = 35) 53.5 (28.0) 45.8 (28.7) 48.0 (25.5) P = 0.008 p = 0.05 p = 0.005
Percent detection of high blood glucose levels
BGAT (n = 33) 45.0 (23.6) 53.1 (25.0) 53.7 (26.2) F(2,126) = 3.54 F(1,63) = 5.93 F(1,63) = 2.62
Control (n = 32) 38.8 (24.0) 33.5 (24.8) 38.2 (23.5) p = 0.03 p = 0.02 p = 0.11
Accuracy Index
BGAT (n = 37) 38.8 (17.1) 45.1 (21.6) 47.3 (21.7) F(2,144) = 7.04 F(1,72) = 5.21 F(1,72) = 11.37
Control (n = 37) 38.5 (17.5) 35.9 (18.5) 34.6 (19.5) p = 0.001 p = 0.02 p = 0.001
Subjective hypoglycemia symptom threshold
BGAT (n = 44) 3.08 (0.73) 3.38 (0.64) 3.30 (0.72) F(2,178) = 2.97 F(1,89) = 5.10 F(1,89) = 1.45
Control (n = 47) 3.25 (0.83) 3.29 (0.75) 3.34 (0.70) p = 0.05 p = 0.02 p = 0.23
Extreme BG fluctuations
Low blood glucose index
BGAT (n = 43) 2.99 (1.54) 2.48 (1.34) 2.61 (1.32) F(2,170) = 0.52 F(1,85) = 0.76 F(1,85) = 0.67
Control (n = 44) 2.62 (1.43) 2.33 (1.44) 2.49 (1.73) p = 0.60 p = 0.39 p = 0.42
High blood glucose index
BGAT (n = 43) 6.53 (3.29) 6.64 (3.37) 6.29 (2.82) F(2,170) = 0.77 F(1,85) = 0.00 F(1,85) = 1.08
Control (n = 44) 5.85 (2.92) 5.95 (3.64) 6.17 (3.35) p = 0.46 p = 0.99 p = 0.30
Glycosylatad hemoglobin (HbA1c)
BGAT (n = 53) 6.93 (0.82) 6.93 (1.02) 6.93 (0.96) F(2,202) = 0.06 F(1,101) = 0.09 F(1.101) = 0.03
Control (n = 50) 6.91 (0.94) 6.95 (0.98) 6.94 (0.94) p = 0.94 p = 0.76 p = 0.85
Note. Severe hypoglycemia (help of others required), BGAT: Blood Glucose Awareness Training, Baseline (T0), 1–6
months (T1), and 7–12 months (T2) follow-up, Means and SD is reported.
(Broers et al., 2002) questioned theeffectiveness of
BGAT. Those investigators tested BGAT in group
vs. individual settings and found the short-term
effects of BGAT to be beneficial, but rather modest,
Table III. Effects of BGAT on Locus of Control
Variable T0 T2
Time × group
interaction; F, p
Locus of control
Internalization
BGAT (n = 54) 38.9 (6.6) 38.6 (7.1) F(1,101) = 0.00
Control (n = 49) 38.4 (6.4) 38.1 (6.6) p = 0.96
Externalization
BGAT (n = 54) 22.4 (7.8) 20.4 (8.0) F(1,101) = 5.43
Control (n = 49) 19.5 (8.4) 19.8 (8.6) p = 0.02
Chance control
BGAT (n = 54) 9.2 (4.6) 8.8 (4.4) F(1,101) = 0.10
Control (n = 49) 9.5 (4.9) 9.4 (5.2) p = 0.75
Unpredictability
BGAT (n = 54) 27.9 (8.2) 24.1 (8.1) F(1,101) = 14.6
Control (n = 49) 26.5 (8.4) 27.2 (8.9) p = 0.0002
Note. BGAT: Blood Glucose Awareness Training; the Locus of
Control questionnaire was not applied at T1, Baseline (T0) and
7–12 month (T2) follow-up, Means and SD is reported.
suggesting that differences between the American
and European samples might affect the reaction
to BGAT. However, those investigators did not
assess long-term effects and used a briefer version
of BGAT (six sessions instead of eight) which might
have accounted for the actual difference. Their nega-
tive finding may also be explained by a lack of power.
Hypoglycemia is the limiting factor in diabetes
insulin therapy (Cryer, 1994). A recent analysis es-
timated the annual rate of severe hypoglycemic
episodes (requiring the help of others) to be 1.5 per
patient in a nonselected population of type 1 diabetes
mellitus patients, 82% of whom were on intensified
insulin therapy (ter Braak et al., 2000). Our sample
had twice this incidence of severe hypoglycemia, pos-
sibly because our samples are older, have longer di-
abetes mellitus duration, are receiving intensified in-
sulin treatment, and were selectively encouraged to
participate in the study if known to suffer from re-
current severe hypoglycemia.
Surprisingly, some BGAT effects were observed
at T1, and others (such as the reduction of severe hy-
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Table IV. Effects of BGAT on Fear of Hypoglycemia
Variable T0 T1 T2
Time × Group
Interaction; F, p
Contrast T1
vs. T0 Group
effect; F, p
Contrast T2
vs. T0 Group
effect; F, p
Hypoglycemia fear survey
Entire sample
Worry
BGAT (n = 53) 16.5 (12.2) 15.2 (12.1) 13.2 (9.9) F(2,198) = 1.03 F(1,99) = 0.01 F(1,99) = 1.39
Control (n = 48) 15.7 (11.7) 14.6 (12.2) 14.7 (12.9) p = 0.36 p = 0.93 p = 0.24
Behavior
BGAT (n = 51) 14.1 (9) 13.7 (8.2) 11.6 (6.9) F(2,194) = 3.47 F(1,97) = 0.25 F(1,97) = 4.85
Control (n = 48) 11.3 (6.6) 11.6 (6.4) 12.2 (8.5) p = 0.03 p = 0.62 p = 0.03
Positive history of severe hypoglycemia within last 2 years
Worry
BGAT (n = 33) 20.6 (12.8) 18.8 (12.5) 15.3 (9.9) F(2,106) = 4.42 F(1,53) = 2.13 F(1,53) = 7.48
Control (n = 22) 17.2 (12.1) 19.1 (14.8) 19.3 (12.9) p = 0.01 p = 0.15 p = 0.01
Behavior
BGAT (n = 32) 16.3 (9.1) 15.1 (8.7) 12.6 (7.9) F(2,104) = 4.1 F(1,52) = 1.24 F(1,52) = 6.46
Control (n = 22) 12.4 (8.1) 13.5 (7.5) 14 (8.7) p = 0.02 p = 0.27 p = 0.01
Note. BGAT: Blood Glucose Awareness Training, severe hypoglycemia (help of others required), Baseline (T0), 1–6
month (T1) and 7–12 month (T2) follow-up, Means and SD is reported.
poglycemia) only at T2. Intensified care provided
by the physician at study entry, or other unspecific
study effects may have been responsible for the low
frequency of severe hypoglycemia at T1 in both the
groups. The increase of severe hypoglycemia rate in
the control group at T2 suggests that this benefit dis-
appeared after another 6 months, when only BGAT
effects were of significant duration. This is consistent
with the previous research which indicated that 12-
months follow-up effects of BGAT were present re-
gardless of whether booster sessions were offered or
not (Cox et al., 2001). BGAT improved the percent
detection of high blood glucose values and increased
subjective hypoglycemia symptom thresholds at T1,
only. Statistical significance at T2 may have been
missed as a consequence of limited power.
Several limitations of this study have to be
considered. It is possible that participants in the
BGAT arm of the study received more physician
attention (two group leaders) than those in the con-
trol group condition (one physician). Furthermore,
the treatments were not of equal length and control
participants were not asked to complete homework
assignments. Additionally, hypoglycemia was not an
obligate topic in the control group meetings. The
appropriateness of the control group intervention is
often subject to discussion in behavioral intervention
trials. Ethical considerations do not allow for the
implementation of inefficient control treatments.
Although blinding of interventions is often advo-
cated, behavioral treatments cannot be delivered
in a truly blinded fashion. Crossover studies, where
patients serve as their own controls, are frequently
complicated by the fact that behavioral treatments,
especially cognitive oriented interventions, have
long lasting effects without return to baseline.
Furthermore, behavioral treatments as well as
control interventions may be sensitive to cultural
differences. These problems cannot be solved within
one trial. Only the homogeneity of different studies
from different cultural backgrounds allows for the
generalization intended.
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Appendix
The following centers participated in the study:
Basel University Hospital (HS, KH, WB and UK),
diabetes outpatient center practice, Olten (MS),
diabetes clinic, Bad Mergentheim (NH), diabetes
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outpatient center practice, Solothurn (Ernst Iff),
diabetes outpatient center practice, Aarau (Ju¨rg
Lareida), diabetes outpatient center practice, Win-
terthur (Elisabeth Nu¨tzi), diabetes outpatient center
practice, Luzern (Frank Ackermann), and Kanton-
spital Luzern (Christoph Henzen).
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